Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma‐derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients ha...

詳細記述

保存先:
書誌詳細
出版年:Br J Haematol
主要な著者: van Velzen, Alice S., Eckhardt, Corien L., Peters, Marjolein, Oldenburg, Johannes, Cnossen, Marjon, Liesner, Ri, Morfini, Massimo, Castaman, Giancarlo, McRae, Simon, van der Bom, Johanna G., Fijnvandraat, Karin
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Platelets, Haemostasis and Thrombosis
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318706/
https://ncbi.nlm.nih.gov/pubmed/32201943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16490
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料